A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts

Simon J Leedham,1,2 Pedro Rodenas-Cuadrado,1 Kimberley Howarth,1 Annabelle Lewis,1 Sreelakshmi Mallappa,2 Stefania Segditsas,1 Hayley Davis,1 Rosemary Jeffery,4 Manuel Rodriguez-Justo,5 Satish Keshav,2 Simon P L Travis,2 Trevor A Graham,4 James East,2 Susan Clark,3 Ian P M Tomlinson

ABSTRACT
Objective Wnt signalling is critical for normal intestinal development and homeostasis. Wnt dysregulation occurs in almost all human and murine intestinal tumours and an optimal but not excessive level of Wnt activation is considered favourable for tumourigenesis. The authors assessed effects of pan-intestinal Wnt activation on tissue homeostasis, taking into account underlying physiological Wnt activity and stem-cell number in each region of the bowel.

Design The authors generated mice that expressed temporally controlled, stabilised β-catenin along the crypt–villus axis throughout the intestines. Physiological Wnt target gene activity was assessed in different regions of normal mouse and human tissue. Human intestinal tumour mutation spectra were analysed.

Results In the mouse, β-catenin stabilisation resulted in a graduated neoplastic response, ranging from dysplastic transformation of the entire epithelium in the proximal small bowel to slightly enlarged crypts of non-dysplastic morphology in the colorectum. In contrast, stem and proliferating cell numbers were increased in all intestinal regions. In the normal mouse and human intestines, stem-cell and Wnt gradients were non-identical, but higher in the small bowel than large bowel in both species. There was also variation in the expression of some Wnt modulators. Human tumour analysis confirmed that different APC mutation spectra are selected in different regions of the bowel.

Conclusions There are variable gradients in stem-cell number, physiological Wnt activity and response to pathologically increased Wnt signalling along the crypt–villus axis and throughout the length of the intestinal tract. The authors propose that this variation influences regional mutation spectra, tumour susceptibility and lesion distribution in mice and humans.

INTRODUCTION
Wnt signalling plays a critical role in the development and homeostasis of the intestinal epithelium. Among other functions, the Wnt pathway is centrally involved in the maintenance of the stem-cell phenotype, control of epithelial cell localisation along the crypt–villus axis, secretory lineage development and the maturation of Paneth cells (reviewed in Scoville et al). The reliance of the intestinal epithelium on physiological Wnt signalling was demonstrated by Kuhnert et al who demonstrated catastrophic loss of adult mouse

Significance of this study
What is already known about this subject?
- Increased Wnt/β-catenin signalling underlies the initiation and progression of gastrointestinal tumours
- An optimal but not excessive level of Wnt activation is considered favourable for tumourigenesis: the ‘just-right’ theory
- There is marked variation in the distribution of murine and human intestinal tumours with a preponderance of small intestinal lesions in the mouse and colorectal tumours in the humans
- Human tumour mutation spectra vary throughout the intestinal tract. For example, microsatellite unstable tumours are predominantly found on the right side of the colon

What are the new findings?
- In a mouse model, stabilisation of β-catenin resulted in graduated neoplastic response down the length of the intestinal tract, with a marked increase in the number of stem and proliferating cells throughout.
- This graduated response mirrored underlying physiological gradients of stem cells, Wnt target gene activity and expression of some Wnt modulators throughout the intestines of normal mice
- Similar but non-identical physiological gradients were found along normal human intestinal tracts and we have confirmed that human tumour APC mutation spectra are selected in different regions of the bowel.
- We propose that variation in stem-cell number and physiological Wnt activity influences regional mutation spectra, tumour susceptibility and lesion distribution.
How might it impact on clinical practice in the near future?  
- This work improves our understanding of the mechanisms behind the non-random tumour distribution in human intestinal cancer.
- Targeted epithelial and mesenchymal manipulation of Wnt in colorectal cancers may prove to be an effective therapeutic strategy.

### Colon

**Significance of this study**

**How might it impact on clinical practice in the near future?**

- This work improves our understanding of the mechanisms behind the non-random tumour distribution in human intestinal cancer.
- Targeted epithelial and mesenchymal manipulation of Wnt in colorectal cancers may prove to be an effective therapeutic strategy.

intestinal epithelial proliferation and crypt structure 7–10 days after adenoviral expression of the Wnt antagonist Dickkopf-1.

Wnt signalling is dysregulated in almost all intestinal neoplasia in the mouse and humans (reviewed by Radtke et al8). The adenomatous polyposis coli (APC) protein is a component of the canonical Wnt signalling pathway and is responsible for the regulation of the transcription factor β-catenin. Truncation or loss of APC disrupts the β-catenin degradation complex, increasing nuclear translocation of this transcription factor and causing increased expression of Wnt target genes (reviewed by Sieber et al9). Germline APC mutations are responsible for familial adenomatous polyposis (FAP), an autosomal dominant condition characterised by the formation of 100’s to 1000’s of colonic polyps. Most patients also develop adenomas of the duodenum, with many developing neoplastic gastric lesions (adenomas or fundic gland polyps) and the severity of colonic, gastric and duodenal polyposis varies within and among families. Somatic mutations in APC are also found in the majority of sporadic colonic adenomas10 and carcinomas.11

In human colorectal tumours, biallelic APC mutations occur non-randomly with respect to one another.12 Mutations are selected on their combined ability to produce an optimal, but not excessive, level of β-catenin activation in the tumour cell, a model subsequently dubbed the ‘just-right’ hypothesis.13 The majority of somatic APC mutations occur between codons 1250 and 1514, termed the mutation cluster region.14 This region of the gene encodes the first three of seven 20-amino acid β-catenin binding repeats (20AARs). Mutations in the mutation cluster region affect the numbers of 20AARs retained by the encoded protein and so alter its ability to bind and degrade β-catenin. In general, retention of a greater number of repeats results in more modest Wnt perturbation in the resultant polyp.

The number of 20AARs retained within a tumour varies according to the region of the intestinal tract in which the lesion is located. In FAP, germline mutations around codon 1300 are associated with copy-neutral loss of heterozygosity (LOH) and a very severe colonic phenotype. This mutation combination results in retention of one 20AAR per allele and is optimally selected in the rectal lesions of germline 1309 patients.10 Severe duodenal polyposis is associated with germline mutations after codon 1400, and somatic mutations that result in a cumulative total of four or more 20AARs in each upper gastrointestinal (GI) lesion are strongly selected.11 Similar variability in mutation distribution is seen in sporadic colorectal tumours, with right-sided tumours retaining significantly more 20AARs than left-sided lesions.12

Analysis of the first hit/second hit relationship in human tissue is observational, based upon the site of APC mutations in established lesions. To further analyse the optimal level of Wnt signalling for tumourigenesis, APC-mutant mice with different numbers of retained 20AARs have been generated. We recently undertook a detailed molecular and phenotypic analysis of two APC-mutant mice on the C57BL/6/12 background, APC<sub>B6(RS10)</sub> and APC<sub>B6(RS10)</sub>13. In tumours from both these animals the ‘second hit’ was LOH by mitotic recombination, resulting in cumulative 20AAR totals of 0 and 2, respectively. Polyp distribution was markedly different in these two strains: APC<sub>B6(RS10)</sub> animals developed a heavy tumour burden in the proximal small bowel (SB1) (segments 1 and 2) whereas APC<sub>B6(RS10)</sub> mice had relatively more polyps in the distal small bowel (SB3) (segments 2 and 3).

Although there are differences between mice and humans, such as intestinal polyp location, the collated data show that an optimal level of Wnt signalling for GI tumourigenesis exists and that this level is submaximal. The evidence also demonstrates that cells of all types in the normal intestine require an optimal Wnt dosage, lower than in tumourigenesis, at different stages of their progression from stem cell—through progenitor, transit amplifying and differentiated phenotypes—to shedding into the gut lumen. We wished to assess how high-efficiency activation of Wnt signalling throughout the intestines would affect cell and tissue homeostasis, taking into account the underlying level of physiological Wnt signalling in each region of the bowel. We chose to study a transgenic mouse that expressed a temporally controlled, stabilised β-catenin protein. This mouse was preferred to APC-mutant animals because β-catenin purely drives canonical Wnt signalling, preventing any hypothetical variation caused by non-LOH second hits at APC, and avoiding the effects of losing non-Wnt functions of Apc.15,16 Here, we report the findings from this mouse and from our subsequent assessment of Wnt signalling in normal mouse and human intestines.

### METHODS

**Transgenic stabilised β-catenin mouse**

Physiological degradation of the β-catenin protein occurs when GSK3β-mediated phosphorylation of serine/threonine residues signals for rapid ubiquitin-dependent proteasomal degradation. These serine/threonine residues are coded for by exon 3 of the gene. Harada et al generated a transgenic mouse with exon 3 flanked by loxP sites (Ctnnb1<sub>lox(ex3)/+</sub>). Recombination with an intestinal driven Cre allowed transgenic in-frame deletion of the entire exon resulting in the expression of degradation resistant β-catenin.17 Subsequently, El Marjou et al demonstrated that a 9-kb regulatory region of the villin gene targeted stable and homogeneous expression of transgenes along the crypt-villus axis in the small and large intestines. We used this inducible Villin-cre system (Villin-Cre<sub>B6(RS1)</sub>) crossed with a Ctnnb1<sub>lox(ex3)/+</sub>/<sub>+/+</sub> mouse on a C57BL/6 genetic background (gift of Mark Taketo) to allow temporal control over pan-intestinal epithelial β-catenin stabilisation in adult animals. Following Cre-mediated recombination, we denoted the mice as Ctnnb1<sub>B6(RS1)</sub>. Genotyping and tissue collection are described in the online supplementary methods.

**Assessment of colonic Cre-mediated recombination**

In order to ensure that Cre recombination occurred uniformly and efficiently in the large intestine of the transgenic animals, we measured the amount of residual β-catenin exon 3 DNA using a standard absolute quantification method (online supplementary methods). Colonic epithelial tissue was laser dissected to minimise contamination from underlying normal stromal tissue and leucocytes. Normalised values for an epithelial cell population were expected to be close to 1 for control animals and 0.5 for heterozygous mice.
Laser capture microdissection and RNA extraction for stem-cell marker qRT-PCR

Six 5 μm serial sections were cut from the wild-type and transgenic colonic tissue blocks used for in situ hybridisation (ISH) and individual crypts were microdissected as previously described. RNA from individual crypts was extracted using Arcturus Paradise FFPE RNA isolation kit (Molecular Devices, Sunnyvale, California, USA) and underwent reverse transcription, amplification and quantitative reverse transcriptase PCR (qRT-PCR).

Immunohistochemistry

Immunohistochemistry for differentiated cell types, cell proliferation, apoptosis and β-catenin expression was completed using standard techniques (online supplementary methods and supplementary table I).

Cell counting and statistical power

Crypt size, cell proliferation, stem-cell number, apoptotic cells and lineage marker expression were compared between a minimum of 100 crypts or crypt-villus units from each intestinal region, from a total of four Ctnnb1Δex3 and wild-type littermates. Cells were counted by three different investigators (SL, PRC, AL), blinded to the mouse genotype. The power to discern differences in cellularity between two intestinal compartments depends upon the magnitude of the difference between the compartments. By contrasting a minimum of 100 crypts from mutant animals to 100 crypts from wild-type animals we were able to detect effect sizes of approximately 0.7 with 99% power (assuming a t test was appropriate to compare between groups of n=100, and requiring a significance level of 0.01).

In situ hybridisation

Mouse model lineage tracing experiments have demonstrated that crypt based columnar cells specifically expressing Leucine rich repeat containing G-protein coupled receptor 5 (Lgr5) are capable of self-replication and multilineage differentiation in the intestine and colon. mRNA ISH for Lgr5 as a putative stem-cell marker was carried out on human duodenal, ileal and colonic biopsies from seven different patients and wild-type and transgenic mouse gut tissue as described in the online supplementary methods.

Normal mouse and human whole mount crypt analysis

Freshly dissected circles of wild-type mouse tissue from the SB1, mid-small bowel (SB2) and SB3, caecum and rectum were obtained using a 2 mm diameter punch biopsy tool. From the

Figure 1 Stabilised β-catenin mouse dysplastic change in the small intestine parallels expansion of proliferating cells with abnormal β-catenin expression. In all intestinal regions there was expansion of the mid-crypt zone. In the proximal small bowel (SB1) this was so pronounced that it destroyed the crypt-villus architecture (Ai). The expanded mid-crypt cell population was dysplastic, actively proliferating (Ki-67 + immunostaining) (Aii) and had abnormal expression of β-catenin (heavy nuclear or cytoplasmic) (Aii). Distal small bowel (SB3) to mid-small bowel (SB2) there was some preservation of normal cell morphology at the crypt bases and villi tips with Ki-67 negative cells (B, Cii) and membranous β-catenin stain (B, Cii). The entire colon was morphologically non-dysplastic with membranous β-catenin staining (Dii); however, there was an expansion and upward shift of the Ki-67+ cells in comparison with wild-type controls (Diii). Expansion of the stem-cell zone using S35-UTP labelled in situ hybridisation for Lgr5 (Aiv–Eiv). There was expansion in the number of Lgr5 expressing cells in all intestinal regions. In the Ctnnb1Δex3 mouse colon the Lgr5+ cells were restricted to crypt bases but filled the bottom third of the phenotypically non-dysplastic crypt (Div), a considerable expansion of the stem-cell compartment in comparison with wild-type mouse colon (Eiv).
human, biopsies of the duodenum, ileum, caecum and rectum were taken from upper and lower endoscopies performed on the same patient. Individual crypts were isolated by whole mount extraction and underwent RNA extraction and qRT-PCR for analysis of Wnt target gene expression (online supplementary methods). The remaining mesenchymal tissue after epithelial denudement was also isolated and processed.

**Archival human sporadic and FAP associated polyps and tumours**

**Tissue collection**

Upper GI biopsies and colectomy specimens from the same FAP patients and sporadic colorectal tumours with a clearly defined colonic location were obtained from pathology archives. Tissue sectioning, DNA extraction, APC sequencing and 5q LOH analysis were completed as previously described (online supplementary methods).

**Public mutation databases**

The APC mutation status of additional sporadic colorectal tumours or cell lines was collected from the Catalogue of Somatic Mutations in Cancer (COSMIC v53 http://www.sanger.ac.uk/genetics/CGP/cosmic/) (online supplementary methods).

**RESULTS**

Pan-intestinal β-catenin stabilisation causes florid dysplasia in the small intestine but not in the colorectum

Four weeks after Cre induction, Ctnnb1<sup>Δex3</sup> animals developed dysplastic changes in the GI tract. The proximal part of the small bowel was grossly thickened with a rubbery texture, but there were no discrete polyps produced either here or in any other part of the intestines. In the duodenum (SB1), microscopic analysis showed that the epithelium was carpeted by high-grade dysplastic cells, with complete destruction of crypt-villus architecture. The morphological appearance gradually improved distally. In the jejunum (SB2), high-grade dysplasia was only ubiquitous at the mid-crypt level. The crypts were greatly enlarged, but there was some preservation of architecture and normal cell morphology, especially at the tips of the villi and bases of the crypts. In the distal ileum (SB3), crypts were enlarged, with a variable mixture of mildly dysplastic and morphologically normal cells extending onto the villi (figure 1). The colon of the Ctnnb1<sup>Δex3</sup> animals was macroscopically normal and microscopically non-dysplastic, but closer examination showed abnormalities. The colorectal crypts of Ctnnb1<sup>Δex3</sup> animals were larger than those of their Ctnnb1-wild-type litter-mates, had significantly more cells (p<0.0001,

| Table 1 Morphological and immunohistochemical findings from different intestinal regions of wild-type and Ctnnb1<sup>Δex3</sup> mice |
|------------------------|------------------------|------------------------|------------------------|------------------------|
|                       | Small bowel segment 1  | Small bowel segment 2  | Small bowel segment 3  | Colon                  |
|                       | WT                     | Ctnnb1<sup>Δex3</sup> | WT                     | Ctnnb1<sup>Δex3</sup> |
| Mean cell number/ crypt (SEM) | 35.3 (0.44) | 36.9 (0.39) | 35.9 (0.4) | 47.1 (0.49) |
| p Value                | NA                     | <0.0001   | <0.0001   | <0.0001   |
| Mean Paneth cells/ crypt-villus cells (per cent (SEM)) | 8.8/97 (9.1% (0.41)) | 11.7/88 (13.3% (0.35)) | 16/169 (9.45% (0.22)) | 10.9/70 (15.53% (0.4)) |
| p Value                | <0.0001   | <0.0001   | <0.0001   | NA         |
| Mean entero-endocrine cells/crypt-villus cells (per cent (SEM)) | 0.9/95.1 (1% (0.26)) | 1.2/149 (1.2% (0.26)) | 0.8/175.7 (0.5% (0.12)) | 0.6/70.4 (1.1% (0.17)) |
| p Value                | <0.0001   | <0.0001   | <0.0001   | NA         |
| Mean goblet cells/ crypt-villus cells (per cent (SEM)) | 7.1/95 (7.2% (0.37)) | 2.1/124.7 (1.7% (0.27)) | 6.1/99.5 (6.9% (0.41)) | 1.9/174.9 (1.1% (0.31)) |
| p Value                | <0.0001   | <0.0001   | <0.0001   | <0.0001   |
| Mean Lgr5+ cells/ crypt-villus cells (per cent (SEM)) | 4.1/94 (4.4% (0.4)) | 150/157.8 (99% (1.3)) | 3.4/92.5 (3.7% (0.23)) | 66/170.2 (50.5% (3.4)) |
| p Value                | <0.0001   | <0.0001   | <0.0001   | <0.0001   |
| Mean Ki-67+ cells/ crypt-villus cells (per cent (SEM)) | 19.2/98 (19.8% (1.16)) | 84.5/149 (56.71% (2.3)) | 23.9/87 (25.3% (1.23)) | 83/161 (52.6% (2.99)) |
| p Value                | <0.0001   | <0.0001   | <0.0001   | <0.0001   |
| Mean number cleaved caspase 3+ cells/1000 nuclei (SEM) | 0.6 (0.04) | 26.5 (1.1) | 0.7 (0.1) | 7.3 (1.3) |
| p Value                | 0.002     | NA        | 0.002     | NA        |
| Mean crypts in fission/ colon (SEM) | 0.002 | NA | 0.002 | NA |
| p Value                | NA        | NA        | 0.002     | NA        |
| β-Catenin immunostain | Membranous | Membranous | Membranous | Membranous |
|                      | Heavy nuclear/cytoplasm | Membranous | Membranous on villi tips and crypt bases. Heavy cytoplasmic elsewhere | Membranous |
|                      |                     | Membranous | Membranous on villi tips and crypt bases. Heavy cytoplasmic elsewhere | Membranous |
|                      |                   | Membranous | Membranous on villi tips and crypt bases. Heavy cytoplasmic elsewhere | Membranous |
|                      |                   | Membranous | Membranous on villi tips and crypt bases. Heavy cytoplasmic elsewhere | Membranous |
|                      |                   | Membranous | Membranous on villi tips and crypt bases. Heavy cytoplasmic elsewhere | Membranous |

The table shows the mean number and percentage of cells per tissue unit on well-orientated cross-sections. A minimum of 50 crypts/crypt-villus units were counted from four different mutant mice. The number of crypts in obvious fission were counted in entire colon rolls from four wild-type and four mutant mice. p Values were calculated using Mann—Whitney U test (Prism, Graphpad Software, La Jolla, California, USA).

**WT**, wild-type.
Mann–Whitney U test) and had a higher prevalence of fission (p=0.03, Mann–Whitney U test) (table 1).

All differentiated cell types were present in dysplastic tissue (table 1). Although there was an absolute increase in small intestinal Paneth cell numbers in transgenic tissue, the increase in crypt size led to transgenic crypts having proportionally fewer of these cells than their wild-type counterparts (p<0.0001, Mann–Whitney U test). Paneth cells were also displaced from the base in mutant crypts (online supplementary figure 1).

Immunohistochemistry showed β-catenin expression in Ctnnb1<sup>Δex3</sup> mice to parallel dysplasia throughout the intestine. In SB1, β-catenin was predominantly heavily nuclear with some regions of cytoplasmic staining. In SB2 and SB3, expression was cytoplasmic in the dysplastic cells in the mid-crypt zone and predominantly membranous otherwise, including at the preserved villus tips in the SB2 to SB3. Membranous β-catenin staining was seen in all morphologically non-dysplastic epithelial cells, including the entire large bowel of Ctnnb1<sup>Δex3</sup> mice and throughout the intestines of control animals (table 1, figure 1).

Cell proliferation marker expression in the Ctnnb1<sup>Δex3</sup> mice

We next assessed the expression of established stem-cell markers in the Ctnnb1<sup>Δex3</sup> mice compared with wild-type animals. ISH demonstrated a huge expansion in the Lgr5-expressing cell population throughout the small intestine. The most pronounced changes were in SB1, where the entire epithelium was Lgr5+. In SB2 and SB3, Lgr5+ cells were predominantly basal, as in normal tissue, although the stem-cell zone was expanded, extending into the mid-crypt region and overlapping with the mid-crypt proliferative/dysplastic zone (figure 1).

**Stem-cell marker expression in Ctnnb1<sup>Δex3</sup> mice**

We next assessed the expression of established stem-cell markers in the Ctnnb1<sup>Δex3</sup> mice compared with wild-type animals. ISH demonstrated a huge expansion in the Lgr5-expressing cell population throughout the small intestine. The most pronounced changes were in SB1, where the entire epithelium was Lgr5+. In SB2 and SB3, Lgr5+ cells were predominantly basal, as in normal tissue, although the stem-cell zone was expanded, extending into the mid-crypt region and overlapping with the mid-crypt proliferative/dysplastic zone (figure 1).
In the large bowel, despite normal morphology, Lgr5+ cells filled the bottom third of the crypt, representing a considerable expansion of the putative stem-cell population in comparison with wild-type controls (figure 1D,E). qRT-PCR on a total of 45 individual laser-microdissected crypts confirmed higher expression of Lgr5 in the large bowel of Ctnnb1Δex3 animals, with a mean 9.2-fold increase (SEM 1.3; p=0.002, t test) compared with wild-type litter-mates. Another colonic stem-cell marker, Ascl2, was also more highly expressed in the mutant animals (mean increase 9.3-fold, SEM 2.3; p=0.02, t test).

Figure 3 Individual crypt Wnt target gene expression varies longitudinally throughout the normal mouse and human intestinal tract. Thumbnail pictures show whole mount intestinal crypts and villi from the different regions of normal mouse and human intestine after EDTA extraction. Mouse villi are pictured purely to provide scale; in fact, only individual crypts were aspirated and used in analysis. Mesenchymal tissue was isolated after complete epithelial denudement. Scale bar 100 µm. Five crypts were dissected from each intestinal region, analysed individually and used to calculate a mean ΔCt, which was then averaged across three wild-type mice (online supplementary table 2A) and four human patients (online supplementary table 2B). Mean ΔΔCt values were used to calculate expression fold changes compared with the region of minimal expression. (A) Mouse gene expression category 1 Wnt target genes (transit amplifying cells) showed quite variable expression along the intestine but were maximally expressed in the proximal small bowel (SB1) (with the exception of Cyclin D1). Category 2 genes (Paneth cells) were expressed in the small intestine as expected from this cell distribution (p<0.001, analysis of variance [ANOVA]). Category 3 genes (stem-cell zone) showed very similar expression profiles with maximal expression in the small intestine declining markedly in the colon with minimal expression seen in the caecum (p<0.001, ANOVA). Sox4 expression closely mirrored that of Ascl2 and a striped line indicates the regions of identical expression. Conversely, epithelial Bmp2 expression was minimal in the duodenum climbing steadily to a peak in the mouse rectum (p<0.001, ANOVA), and there was also significant variability in the expression of some of the mesenchymal Wnt modulators (Grem2 and Hgf, p<0.05, ANOVA). The expression of the mesenchymal Wnt antagonist, Sfrp2, varied considerably with colonic expression more than 130-fold greater than that in the small intestine (p=0.035, ANOVA). (B) Human gene expression. All human Wnt target genes were maximally expressed in the ileum and minimally expressed in the rectum with the exception of the category 1 genes LEF1 and CYCLIN D1 (CCND1), which were maximally expressed more proximally. Category 3 (stem-cell) gene expression peaked in the ileum correlating with the human in situ findings (p<0.001, ANOVA). Caecal stem-cell marker expression is significantly greater than that seen in the rectum. The inverse correlation was seen for epithelial BMP2 expression (p<0.001, ANOVA). Expression of the mesenchymal Wnt modulators was generally higher in the human small intestine which contrasted sharply with the murine Gremlin 1, 2 and Sfrp2 expression gradients. Only the expression gradient for HGF reached statistical significance in the humans (p=0.09, ANOVA) as the result of a 10-fold difference in expression from the caecum to the rectum. SB1, proximal small bowel; SB2, mid-small bowel; SB3, distal small bowel.

Colon

Gut 2013;62:83–93. doi:10.1136/gutjnl-2011-301601

on April 21, 2022 by guest. Protected by copyright.

Figure 3 Individual crypt Wnt target gene expression varies longitudinally throughout the normal mouse and human intestinal tract. Thumbnail pictures show whole mount intestinal crypts and villi from the different regions of normal mouse and human intestine after EDTA extraction. Mouse villi are pictured purely to provide scale; in fact, only individual crypts were aspirated and used in analysis. Mesenchymal tissue was isolated after complete epithelial denudement. Scale bar 100 µm. Five crypts were dissected from each intestinal region, analysed individually and used to calculate a mean ΔCt, which was then averaged across three wild-type mice (online supplementary table 2A) and four human patients (online supplementary table 2B). Mean ΔΔCt values were used to calculate expression fold changes compared with the region of minimal expression. (A) Mouse gene expression category 1 Wnt target genes (transit amplifying cells) showed quite variable expression along the intestine but were maximally expressed in the proximal small bowel (SB1) (with the exception of Cyclin D1). Category 2 genes (Paneth cells) were expressed in the small intestine as expected from this cell distribution (p<0.001, analysis of variance [ANOVA]). Category 3 genes (stem-cell zone) showed very similar expression profiles with maximal expression in the small intestine declining markedly in the colon with minimal expression seen in the caecum (p<0.001, ANOVA). Sox4 expression closely mirrored that of Ascl2 and a striped line indicates the regions of identical expression. Conversely, epithelial Bmp2 expression was minimal in the duodenum climbing steadily to a peak in the mouse rectum (p<0.001, ANOVA), and there was also significant variability in the expression of some of the mesenchymal Wnt modulators (Grem2 and Hgf, p<0.05, ANOVA). The expression of the mesenchymal Wnt antagonist, Sfrp2, varied considerably with colonic expression more than 130-fold greater than that in the small intestine (p=0.035, ANOVA). (B) Human gene expression. All human Wnt target genes were maximally expressed in the ileum and minimally expressed in the rectum with the exception of the category 1 genes LEF1 and CYCLIN D1 (CCND1), which were maximally expressed more proximally. Category 3 (stem-cell) gene expression peaked in the ileum correlating with the human in situ findings (p<0.001, ANOVA). Caecal stem-cell marker expression is significantly greater than that seen in the rectum. The inverse correlation was seen for epithelial BMP2 expression (p<0.001, ANOVA). Expression of the mesenchymal Wnt modulators was generally higher in the human small intestine which contrasted sharply with the murine Gremlin 1, 2 and Sfrp2 expression gradients. Only the expression gradient for HGF reached statistical significance in the humans (p=0.09, ANOVA) as the result of a 10-fold difference in expression from the caecum to the rectum. SB1, proximal small bowel; SB2, mid-small bowel; SB3, distal small bowel.

Gut 2013;62:83–93. doi:10.1136/gutjnl-2011-301601

on April 21, 2022 by guest. Protected by copyright.
underlying physiological gradients and so we also investigated the cephalo-caudal stem-cell and Wnt signalling gradients in the GI tract of wild-type litter-mates.

First, we used high-resolution H-UTP in situ assessment of mRNA for the stem-cell marker Lgr5 on well-orientated crypts (figure 2A) to allow accurate counting of the number of cells expressing stem-cell markers in the different intestinal regions. Lgr5 ISH showed a gradually decreasing stem-cell number progressing from SB1 to SB3, but then a marked reduction in the large bowel (ANOVA p=0.001) (figure 2B).

Next, we identified robust Wnt target genes based on consistent changes in a combination of experiments (details not shown): lithium chloride inhibition of GSK3β in the normal RI3-1 intestinal cell line (Leedham, unpublished data, 2010) and exon mRNA expression microarray and qRT-PCR in tumours from Apc-mutant mice. Wnt target genes were chosen and subdivided into the categories defined by Van der Flier et al.22

1. genes expressed in the rapidly dividing transit amplifying cells (Axin2, EphB2, CyclinD1, Left)
2. genes expressed by post-mitotic Paneth cells (EphB3, Mmp7 (mouse only))
3. genes expressed in the stem-cell position of the crypt (Lgr5, Olfm4 and Ascl2 (mouse only), Sox4 (mouse only)).

We then used qRT-PCR assays of identified Wnt target gene mRNA in order to measure overall expression levels in individual crypts taken from different regions of the mouse intestine (figure 3A and online supplementary table 2A). Wnt target gene expression varied considerably down the length of the intestinal tract (figure 3A), with expression in the small bowel greater than that in the colon, correlating with the Lgr5 ISH findings. Minimal Wnt target expression was seen in the caecum.

We also demonstrated variability in the regional expression of some established epithelial and mesenchymal Wnt modulators (figure 4A and online supplementary table 2A). There was a considerable gradient in expression of the Wnt antagonist Sfrp2 in the mouse, with mesenchymal expression in the colon more than 150-fold greater than that in the small intestine. Sfrp2 is a potent inhibitor of endogenous Wnt activity in rat normal intestinal epithelial cells (online supplementary results, online supplementary figure 2), and so its high expression is likely to contribute to the low epithelial Wnt activity in the mouse large bowel. Dickkopf 1, 2, 3 and R-spondin 1, 2, 3 expression were also measured but no appreciable intestinal gradient detected (data not shown).

**Human tumour mutation spectra and Wnt gradient in the normal human intestines**

In *Canibrs* mice, the distribution of dysplasia paralleled the physiological Wnt and stem-cell gradient. β-Catenin mutations are, however, rare in human bowel tumours which usually dysregulate Wnt through APC mutations. These mutations are under selective constraints such that stem cells acquire an optimal but not excessive level of Wnt signalling.6 7 Existing data from different FAP patients support the existence of different APC mutation spectra in tumours from different locations in the bowel.10 12 23 In order to compare the somatic mutation profiles of upper and lower GI tumours from the same patient, we studied a new set of FAP patients from whom gastric/duodenal and colonic lesions had been sampled. This allowed us to control for the effects of variation among patients and potential confounding factors such as diet. We demonstrated that upper GI lesions in FAP retain significantly more 20AARs than lower GI lesions taken from the same patient (figure 4 and online supplementary table 3).
Figure 5  ‘Just-right’ theory and genotype-phenotype correlations. (Ai and Bi) Basal Wnt signalling and stem-cell number in the mouse and humans. Mouse and human basal Wnt target expression profile and stem-cell number vary down the length of intestinal tract (figure 3). The two species have quite distinct profiles which in combination with ‘just-right’ mutation spectra may contribute to intestinal lesion distribution. (Aii and Aiii) The consequences of pathological Wnt signalling in the mouse. Submaximal pathological Wnt perturbation (seen in Ctnnb1Dex3 and Apc1322T mice, as evidenced by low levels of nuclear β-catenin expression) breaches the dysplasia threshold in the proximal small intestine where basal Wnt expression and stem-cell numbers are the highest, resulting in a heavy proximal small bowel (SB1) and mid-small bowel (SB2) lesion burden. In the mouse colon, the Wnt perturbation is insufficient to cause dysplasia in the colon despite causing an increase in the stem-cell number. Maximal Wnt perturbation as seen in the ApcMin(R850X) is excessive and thus suboptimal proximally; hence, a predominantly distal small bowel (SB3) polyp distribution is characteristic. Maximal lesion distribution shown with dark red shading. (Bii and Biii) The consequences of pathological Wnt signalling in the humans. Modest Wnt perturbations such as that resulting from mutations that retain several 20-amino acid β-catenin binding repeats (20AARs)
Next, we genotyped and examined the mutation spectra of 19 sporadic colorectal cancers with known colonic distribution. This was combined with the data from 57 other sporadic tumours and cell lines taken from COSMIC v53. We only included lesions where we could identify both somatic hits at APC to give an accurate measure of the number of retained 20AARs (online supplementary table 4A,B). Right-sided lesions (transverse, ascending colon and caecum) had a higher frequency of mutations that retained a total of three or more 20AARs than left-sided colonic lesions (descending colon, sigmoid and rectum) (χ² test, p=0.03). These data validate and add to the work by Albuquerque et al. demonstrating that the optimal tumourigenic level of Wnt signal varies within the different regions of the colon in sporadic tumours as well as between the colon and small intestine in FAP (figure 4, online supplementary tables 3 and 4).

To our knowledge, physiological stem-cell and Wnt gradients have not previously been investigated in the normal human intestine. Based on our findings in the mouse we hypothesised that such gradients might contribute to established human tumour selective constraints. First, we assessed LGR5 mRNA expression in normal intestinal biopsy tissue taken from the duodenum, ileum and colon of the same patients. In contrast to the mouse, maximal stem-cell marker mRNA expression was seen in the ileum in humans (figure 2C).

Next, human Wnt target genes were chosen and categorised as for the mouse and their expression levels assayed in isolated crypts by qRT-PCR. Similar to the mouse, normal human Wnt target gene expression showed considerable variability down the length of the intestinal tract (figure 3B and online supplementary table 2B). However, the majority of genes were maximally expressed in the ileum, consistent with the human LGR5 ISH results. Epithelial BMP2 and mesenchymal BMP antagonist expression was consistent with the observed stem-cell gradient. Mesenchymal HGF expression varied 10-fold between the caecum and rectum. As this is a potent morphogen that promotes nuclear β-catenin translocation in human CRC cells, this gradient may contribute to the observed difference in epithelial Wnt target gene activity between the human caecum and rectum. Dickkopf 1, 2, 3 and R-spondin 1, 2, 3 expression was also measured but no appreciable intestinal gradient was detected (data not shown).

DISCUSSION

Intestinal cell fate is determined by morphogen concentration gradients, mediated by complex interactions between an array of signalling molecules, receptors and antagonists. The importance of the Wnt pathway in the control of cell proliferation and the maintenance of intestinal stem cells is well established. Here, we have demonstrated variable stem-cell number and physiological Wnt pathway activity in different regions of the normal murine and human intestinal tracts.

Using a mouse model, we have also shown a graduated response to β-catenin stabilisation. All regions of the intestines showed an expansion of two overlapping populations of cells: (1) stem cells, predominantly at the crypt base and (2) proliferating, dysplastic cells, usually at the mid-crypt zone. The most profound changes were in SB1, where the entire epithelium was disordered and filled with stem-like, proliferating cells. In the large bowel, this stem and proliferating cell expansion was coupled with an increase in the crypt size and rate of fission, but normal architecture was largely retained and there was no dysplasia. As Villin-CreER(T2) drives Cre-mediated recombination homogenously throughout the crypt-villus axis and along the intestines, these data suggest an inherently variable response to increased Wnt signalling. Kuhnert et al. showed that the effect of systematically antagonising Wnt by Dickkopf-1 expression similarly varied down the length of the murine intestine with the most profound effect in SB1. We demonstrated that this intrinsic sensitivity to Wnt modulation along the caudal-cephalic axis of the intestine mirrored the physiological gradient expression of the stem-cell markers Lgr5 and Olfm4. Recent work has shown that the stem-cell marker Lgr5 functions as a Wnt receptor component that mediates Wnt signal enhancement via soluble R-spondin protein. As a Wnt signalling enhancer and target gene, Lgr5 appears to be subject to positive auto-regulation corroborated by the marked expansion of the Lgr5 expressing cell population following β-catenin stabilisation here, and in response to the Wnt agonist R-spondin. As physiological R-spondin expression was consistent throughout the intestine we hypothesise that an intestinal gradient of Lgr5 expression may influence this regional inherent sensitivity to Wnt signalling and the response to pathological Wnt excess.

An intriguing question is whether the differences in dysplasia along the intestines of the Cmbfr(−/−) mouse are related to our previous observations’—confirmed in this manuscript—that specific APC mutation spectra are optimally selected in different regions of the human bowel. These observations, dubbed the ‘just-right’ model, propose that a threshold of Wnt signalling needs to be reached for dysplastic lesions to form, but that the optimum Wnt level for tumourigenesis is submaximal. Our mouse and human data provide clues to suggest that one reason for different APC mutations in tumours along the GI tract is a different physiological level of Wnt and stem-cell number. Hence, for example, when a modest pathological Wnt perturbation is superimposed on a low level of physiological Wnt—as in the colon of Cmbfr(−/−) mice—the resultant Wnt level is still too low to cause dysplasia (figure 5A). In humans, the caecum has higher Wnt levels than the rectum, consistent with the selection of mutant APC alleles that retain a greater number of 20AARs. In microsatellite unstable cancers, this selection is favoured by the presence of multiple mononucleotide and dinucleotide repeats between codons 1450 and 1560 of APC that are prone to slippage in mismatch repair deficiency. Along with Albuquerque et al., we speculate that it is this retention of 20AARs in mismatch repair deficient tumours that accounts for the right-sided colonic distribution of these tumour types.

Homeostatic Wnt signalling and stem-cell numbers in the normal intestine are subject to auto-regulatory and combinatorial control with a complex network of interacting mesenchymal and epithelial morphogenetic pathways. We have demonstrated intestinal gradients of some important Wnt and
stem-cell modulators such as Bmp2, Gremlin 1, 2 and Hgf in the epithelium and mesenchyme of humans and mice. Variable mesenchymal-epithelial cross talk along the intestinal tract is likely to influence physiological epithelial Wnt activity. In particular, the marked Sfrp2 expression gradient between the mouse colon and small intestine may contribute to the very low level of physiological epithelial Wnt activity seen in the murine colon, as we have shown that Sfrp2 is a potent and dose-dependent antagonist of endogenous Wnt activity (online supplementary figure 2). As this gradient in the mouse is the reverse of that seen in the humans (online supplementary figure 2), we hypothesize that the antagonism of Wnt activity by factors such as Sfrp2 in the mouse colon may contribute to the differential intestinal polyyp distribution in humans and mice. Interestingly, van Veelen et al have recently shown that coactivating intestinal Wnt signalling by Apc deletion and by a mechanism mimicking receptor tyrosine kinase phosphorylation of β-catenin markedly shifted murine intestinal tumour distribution towards the colon.29 This suggests that the maintenance of low physiological Wnt activity in the mouse colon by ligand sequestering antagonists such as Sfrp2 may be partially counteracted by pathological activation of Wnt via an alternative (Wnt ligand and Frizzled receptor independent) mechanism, resulting in sufficient Wnt activity to breach the colonic Wnt signalling threshold and initiate colonic tumour formation. Regional variation in tyrosine kinase receptor expression has been reported in the normal human colon with epidermal growth factor receptor expression significantly higher proximally,30 correlating with the higher physiological Wnt activity we have demonstrated in the right human colon. Furthermore, variation in the pattern of epigenetic change has also been reported in the normal human large intestine.31 Methylation and transcriptional silencing of Wnt signalling genes have been shown to occur in morphologically normal crypts,32 and are common in colorectal tumours.33 Physiological regional variation in epigenetic transcriptional silencing or non-canonical Wnt activation may contribute to the marked variability in Wnt target gene activity demonstrated here.

We have generated a simple model in an attempt to explain multiple genetic events and complex physiological pathways and recognise the limitations of attempting to do this. There are a number of phenomena that this model cannot explain such as the disparity in prevalence between sporadic duodenal and caecal lesions in humans despite similar basal Wnt and stem-cell numbers in these two regions. While these data support the influence of Wnt signalling and stem-cell number variation on tumour distribution, there are also a number of potential confounding factors that have not been assessed such as the effect of intraluminal toxins and the contribution of the intestinal flora.

We propose that variable gradients in physiological Wnt activity and stem-cell number influence Wnt responsiveness along the crypt-villus and caudal-cephalic axes of the intestinal tract and that this influences regional intestinal mutation spectra and tumourigenic susceptibility. Identifying the homeostatic factors and Wnt modulators responsible for maintaining these gradients is likely to remain an area of research interest as the potential for therapeutic manipulation of Wnt in the colorectum remains a tantalising prospect.

Acknowledgements The authors thank the Animal technician staff at Cancer Research UK Clare Hall facility.

Funding This work was supported by Cancer Research UK (Clinician Scientist Fellowship to SJL) and the Wellcome Trust (CORE GRANT 080532/Z/09/2).

Competing interests None.

Ethics approval All mouse work was approved by the UK Home Office and local ethics committee. Human archival tissue was obtained from St Marks Hospital, Harrow with multicentre ethics approval (MREC05/01606/66). Endoscopic biopsy tissue was obtained from the John Radcliffe Hospital, Oxford with local REC approval (REC 10/1606/04/2).

Contributors Data acquisition by SJL, PRC, KH, AL, SS, HD, RJ and TAG. Pathology and material support by SM, MRJ, SK, SPT, JE and SC. Study design and paper authorship by SJL and IPMT.

Provenance and peer review Not commissioned; internally peer reviewed.

Data sharing statement Unpublished data on lithium chloride stimulation of RIE cells and Dickkopf-1 and P-Snordin Wnt modulator expression are available on request to the corresponding author.

Open access This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial, Non-Derivatives License, which permits use, distribution, and reproduction as is in any medium, provided the original work is properly cited, the work is not altered, the use is non-commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc-nd/3.0/ and http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode.

REFERENCES

1. Scoville D, Sato T, He X, et al. Current view: intestinal stem cells and signaling. Gastroenterology 2008;134:65–64.
2. Kuhner F, Davis CR, Wang HT, et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A 2004;101:286–71.
3. Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Curr Mol Med 2006;6:275–9.
4. Sieber OM, Tomlinson IP, Lammli H. The adenomatous polyposis coli (APC) tumour suppressor—genetics, function and disease. Mol Med Today 2000;6:662–9.
5. Powell SM, Zit N, Bauser-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235–7.
6. Miyoshi Y, Nagase H, Aoda H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229–33.
7. Lamliu H, Iyai M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson’s ‘two-hit’ hypothesis. Nat Med 1999;5:1071–5.
8. Albuquerque C, Breukel C, van der Luijt R, et al. The ‘just-right’ signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 2002;11:1549–60.
9. Nagase H, Miyoshi Y, Hori A, et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 1992;52:4055–7.
10. Will O, Leedham S, Eka G, et al. Location in the large bowel influences the APC mutations observed in FAP adenomas. Fam Cancer 2010;9:389–93.
11. Groves CJ, Saunders BP, Speigelman AD, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002;50:636–41.
12. Albuquerque C, Battazar C, Filipe B, et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer 2010;49:746–59.
13. Lewis A, Segdittas S, Deherogada M, et al. Severe polyposis in Apc(1322T) mice is associated with submaximal Wnt signalling and increased expression of the stem cell marker Lgr5. Gut 2010;59:1680–6.
14. Pollard P, Deherogada M, Segdittas S, et al. The Apc 1322T mouse develops severe polyposis associated with submaximal nuclear beta-catenin expression. Gastroenterology 2009;136:2204–13.e1–13.
15. Samsom OJ, Reed KR, Hayes AJ, et al. Loss of APC in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004;18:1385–96.
16. Fodde R, Kupers J, Rosenberg C, et al. Mutations in the APC tumor suppressor gene cause chromosomal instability. Nat Cell Biol 2001;3:433–8.
17. Harada N, Tama Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999;18:5381–42.
18. El Marjou F, Janssen K, Chang B, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004;39:186–93.
19. Thrivelogic E, Will O, Domingo E, et al. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyyclonality of colorectal adenomas. Gastroenterology 2010;138:1441–51.e4–7.
20. Barker N, van Es J, Kupers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003–7.
21. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1648–58.
22. Van der Flier LG, Sobates-Bellier J, Oving I, et al. The intestinal Wnt/Tcf signature. Gastroenterology 2007;132:626–32.
23. Groves C, Lamium H, Crabtree M, et al. Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 2002;160:2055–61.

24. Vermeulen L, De Sousa EMF, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:488–96.

25. de Lau W, Barker N, Low TY, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011;476:293–8.

26. Ootani A, Li X, Sangiorgi E, et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med 2009;15:701–6.

27. Albuquerque C, Bakker ER, van Veelen W, et al. Colorectal cancers choosing sides. Biochim Biophys Acta 2011;1816:219–31.

28. Crosnier C, Stamatakis D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006;7:349–59.

29. van Veelen W, Le NH, Helvensteijn W, et al. β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011;60:1204–12.

30. Koenders PG, Peters WH, Wobbes T, et al. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 1992;65:189–92.

31. Figueiredo JC, Grau MV, Wallace K, et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev 2009;18:1041–9.

32. Belshaw NJ, Pal N, Tapp HS, et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis 2010;31:1158–63.

33. Segditsas S, Sieber OM, Rowan A, et al. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol 2008;85:201–6.
Supplementary information.

A basal gradient of Wnt and stem-cell number influences regional tumor distribution in human and mouse intestinal tracts

Supplementary Methods

Ethics and animal husbandry
All mouse work was approved by the UK Home Office and local ethics committee. Mice were housed in the barrier unit of Cancer Research UK, Clare Hall Laboratories. Human archival tissue was obtained from St Marks Hospital, Harrow with multicentre ethics approval (MREC05/Q1606/66). Endoscopic biopsy tissue was obtained from the John Radcliffe Hospital, Oxford with local REC approval (REC 10/H0604/72)

Transgenic stabilized β-catenin mouse
Animal breeding and collection of samples
Mice were genotyped for exon 3 excision using the following primers: β-catenin exon 3 forward GCTGCGTGGACAATGGCTAC, reverse GCTTTTCTGTCCGGGCTCCAT giving approximately 350bp fragment for mutant alleles and a 550bp fragment for wild-type alleles. Cre recombinase was detected with: forward CGGTCGATGCAACGAGTGATGAGG and reverse CCAGAGACGGAAATCCATCGCTCG primers. Intra peritoneal tamoxifen (5 consecutive days of 100µl of 10mg/ml tamoxifen) initiated Cre recombination in 6 week old mice, as mice of this age have undergone post-natal intestinal crypt clonal purification and are maintained on an adult diet. Mice were sacrificed at a specified time after recombination or when symptomatic (anaemic secondary to intestinal lesions or experiencing rectal prolapse). The mean time to sacrifice was 5 weeks. The intestinal tract was divided into four segments - three equal length segments of small bowel (proximal SB1, middle SB2 and distal SB3) and the colon. Each segment was flushed with phosphate buffered saline, opened longitudinally and laid out on filter paper. The samples were fixed in 10% neutral buffered formalin for 24 hours and stored in 70% ethanol. Histology samples were processed using standard methods.
Assessment of colonic Cre-mediated recombination.

Formalin fixed paraffin embedded (FFPE) colonic sections from three heterozygotes (Ctnnb1Δex3/+ ) and four wild-type mice were digested overnight with 30µL of Picopure™ proteinase K. TaqMan assays were designed and optimized by Applied Biosystems (Applied Biosystems, Carlsbad, Ca, USA) to the exon 3 region of the β-catenin gene, which is deleted in the genetically modified mice and to the exon 6 region of ribonuclease P protein subunit p30 gene (Rpp30), chosen as an endogenous control following the manufacturer's recommendation. Standard curves were set up using six consecutive 2-fold dilutions of DNA extracted from a wild type mouse and were run for both β-catenin and Rpp30 at all times. Colonic epithelial tissue was laser dissected away from the contaminating stroma and extracted DNA from wild-type and heterozygous mutant mice were run on the same plates and the amount of residual β-catenin exon 3 DNA was automatically inferred by the program from the standard curve for each gene. Values for β-catenin were then normalized to those for the endogenous control Rpp30.

Immunohistochemistry

Gut roll sections were de-waxed and rehydrated by standard methods. Endogenous peroxidase was blocked with 3% H2O2 in methanol for 10 minutes. Antigen retrieval was achieved by 10 minutes pressure-cooking in sodium citrate buffer at pH 6. Slides were incubated in 3% bovine serum albumin in phosphate buffered saline (PBS) for 15 minutes. Slides underwent primary antibody incubation with varying dilutions of different mouse monoclonal antibodies (Supplementary table 1). This was followed by 1:500 dilution biotinylated rabbit anti-mouse secondary antibodies (DAKO, Glostrup, Denmark) before application of a 1:500 dilution of the tertiary layer of peroxidase-conjugated streptavidin (strept-HRP: DAKO, Denmark). Each layer was applied for 45 minutes and three 5-minute PBS washes were performed between layers. Sections were then developed with 3,3-diaminobenzidine-tetrahydrochloride solution (DAB; Sigma, Gillingham, UK) for 2 minutes, followed by rinsing in tap
water and light haematoxylin counterstaining. Negative controls underwent all steps but were incubated with PBS instead of the primary antibody solution.

**In situ hybridization**

4µm serial sections of formalin fixed paraffin-embedded human duodenal, ileal and colonic biopsies from 11 different patients and wild-type and transgenic mouse gut rolls were cut. Exon-spanning riboprobes were designed for human and mouse *Lgr5* and a *β-actin* probe was used for hybridization control. Riboprobes were generated by in vitro transcription using SP6 polymerase and labeled with S°-UTP (human and mouse *Lgr5*) or H°-UTP (mouse *Lgr5* only) (GE Healthcare, Chalfont St Giles, UK). Other methods were as described by Poulson *et al* 1 In H°-UTP based assays on normal mouse intestines, the number of *Lgr5* positive cells (≥4 silver granules present) per crypt were counted by three different investigators (PRC, AL, SJL) on 100 crypts from each region in three different wild-type animals.

**Normal mouse and human whole mount crypt analysis.**

*Tissue processing*

Tissue was incubated in 5mls of Dulbecco’s modified Eagle medium (Invitrogen) with added 30mmol/L ethylenediaminetetraacetic acid (EDTA; Sigma, UK), 0.1 mol/L dithiothreitol, and 100µl RNA later solution (Ambion, Austin, TX, USA) for 15 minutes. Tissue was transferred to phosphate buffered saline (PBS) and then vigorously shaken for 20 seconds. Individual intestinal crypts were then drawn up using glass pipettes and transferred to RNA lysis buffer (Qiagen, Crawley, UK). After several cycles of shaking with fresh PBS washes, complete epithelial denudement occurred and the residual mesenchymal tissue was collected and processed.

*RNA extraction, reverse transcription and quantative PCR (qRT-PCR)*

RNA was extracted from individual whole mount crypts using the RNAeasy Micro kit (Qiagen, UK) which includes an on-column DNase step. Obtained RNA quality was assessed on a Bioanalyser (Agilent, Santa Clara, Ca, USA). Reverse transcription was completed straight after RNA extraction using ABI high
capacity RNA to cDNA kit (Applied Biosystems, Carlsbad, Ca, USA). Taqman Pre-Amp Mastermix (Applied Biosystems, USA) was used to pre-amplify individual crypt cDNA. The intron-spanning pre-optimized Taqman probes used, were assessed using control cDNA to ensure that no amplification bias was introduced. Quantitative RT-PCR was carried out on a 7900 Fast real-time PCR machine (Applied Biosystems, USA) using the same Taqman probes used for pre-amplification. Results were normalized to GAPDH and analysis was completed using the standard ΔΔCt method.

**Tissue culture**
The rat RIE-1 small intestinal cell line was grown in RPMI medium with 10% foetal calf serum (FCS). Cells were plated out and left to grow to about 80% confluence. Following serum starvation for 24 hours, fresh serum-free medium supplemented with increasing doses of recombinant mouse Sfrp2 was added (Sfrp2 at 15nM, 150nM and 300nM concentrations). Cells were harvested after 4 hours, RNA was extracted and underwent DNAse treatment and reverse transcription. qRT-PCR was then carried out for Axin2, an established Wnt target gene in these cells (Leedham 2010, unpublished) to assess the effect of Sfrp2 on endogenous Wnt target gene expression.

**Archival human sporadic and FAP associated polyps and tumors**

*Tissue processing*
Serial sections were cut from each block, dewaxed and carefully needle dissected using an H&E stained slide as a guide. Muscularis mucosa tissue was taken from colectomy specimens for constitutional DNA. Dissected tissue was digested overnight in 40μL of Picopure™ proteinase K (Arcturus Bioscience, Mt View, CA). DNA was extracted and used for APC sequencing and 5qLOH analysis.

*APC sequencing and 5qLOH analysis*
DNA underwent sequencing of the mutation cluster region of APC using previously described primers and PCR conditions. All samples were sequenced directly in forward and reverse orientation from a new PCR product. APC codons 1-1220 were also sequenced in one sample in an attempt to find mutations 5’ to
the MCR. All samples underwent 5q LOH assessment using microsatellite markers D5S346, D5S421 and D5S646. Forward primers were labeled with a FAM or HEX fluorescent tag allowing identification of the two separated alleles using GENOTYPER software (Perkin-Elmer, Waltham, MASS, USA). Constitutionally homozygous markers were scored as non-informative. LOH at each marker was considered present if the area under one allelic peak in the affected crypt was less than 0.5 times or greater than 2 times that of the other allele, after normalizing the peak areas relative to constitutional DNA.

Data collection from public mutation databases (COSMIC v53)

Data were selected if both the mutation status of each APC allele was known (truncating mutation or LOH), and if adequate positional information to determine tumour location in the colon (right colon or left colon) was available. The number of retained 20AAR's on each mutated allele was calculated as described in the supplementary methods.

Calculation of retained 20AAR's

The total number of remaining 20AARs on the mutated allele(s) was calculated for each tumor; in cases where the tumor had two truncating APC mutations this was the sum of the number of 20AARs remaining on each allele; in cases where the tumor had LOH the total number of retained 20AARs was assumed to be twice the number retained on the truncated allele due to mitotic recombination.

Supplementary results

Recombinant Sfrp2 antagonises endogenous Wnt activity in RIE-1 cells.

The secreted frizzled related proteins share sequence homology with the frizzled Wnt receptor and were initially identified as secreted extracellular attenuators of Wnt, exerting their antagonistic effect by binding and sequestering Wnt proteins. In a comprehensive assessment of Sfrp action in chick neural tube cells, Sfrp2 was shown to be the most effective wnt antagonist inhibiting both endogenous and ectopic Wnt-3a induced β-catenin accumulation. However subsequent studies in neonatal mouse intestinal cells kidney and salivary gland
cells \(^5\) demonstrated that Sfrp2 enhanced the effect of recombinant Wnt-3a promoting nuclear \(\beta\)-catenin accumulation and resulting in Wnt target gene expression.

We have shown that physiological Sfrp2 expression varies considerably in the mouse intestine with colonic mesenchymal expression more than 130 fold greater than that seen in the small intestine. Furthermore this gradient is the reverse of that seen in the human (supplementary figure 1). In order to assess the effects of Sfrp2 on endogenous Wnt activity in a normal rodent intestine cell system we measured Wnt target gene expression in response to physiological and supra-physiological doses of recombinant Sfrp2. In this cell system we saw a dose dependent decrease in wnt target gene activity following incubation with recombinant Sfrp2, demonstrating that in rodent intestinal cells, Sfrp2 antagonises endogenous Wnt activity.
### Supplementary table 1

| Antibody | Specificity                  | Species | Dilution | Antigen retrieval                        | Source            |
|----------|------------------------------|---------|----------|------------------------------------------|-------------------|
| **Primary antibody** |                              |         |          |                                          |                   |
| β-catenin (610154) | Activation of Wnt pathway     | Mouse   | 1:100    | Pressure cook in sodium citrate buffer   | BD Biosciences    |
| Ki-67 (MIB1) (M7249) | S-phase marker                | Rat     | 1:125    | Pressure cook in sodium citrate buffer   | DAKO              |
| Cleaved caspase 3 (AF835) | Apoptotic cells              | Rabbit  | 1:800    | Pressure cook in sodium citrate buffer   | R&D systems       |
| Lysozyme (A0099) | Paneth cells                  | Rabbit  | 1:500    | Pressure cook in sodium citrate buffer   | DAKO              |
| Chromogranin A (15160) | Entero-endocrine cells        | Rabbit  | 1:1000   | Pressure cook in sodium citrate buffer   | Abcam             |
| **Secondary antibody** |                              |         |          |                                          |                   |
| IgG Biotin conjugate | Anti-mouse                   | Rabbit  | 1:300    | Applied as secondary layer               | DAKO              |
| IgG Biotin Conjugate | Anti-rabbit                  | Goat    | 1:300    | Applied as secondary layer               | Molecular Probes  |

**Supplementary table 1. Antibodies, dilutions and conditions.**
## Supplementary table 2A: Mouse whole mount crypt gene expression by qRT-PCR

| Epithelial Gene/patient | SB1 | SB2 | SB3 | Caecum | Rectum |
|-------------------------|-----|-----|-----|--------|--------|
|                         | Mean (SEM) ΔCt | ΔΔCt | Mean (SEM) ΔCt | ΔΔCt | Mean (SEM) ΔCt | ΔΔCt | Mean (SEM) ΔCt | ΔΔCt | ANOVA |
| **Ascl2**               |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 5.6 (0.09) | -1.59 | 5.8 (0.16) | -1.39 | 5.7 (0.49) | -1.5 | 7.2 (0.17) | 0 | 7.2 (0.36) | -0.03 |
| Mouse 2                | 5.2 (0.26) | -3.67 | 6.7 (0.07) | -2.13 | 7.9 (0.17) | -1 | 8.9 (0.27) | 0 | 7.6 (0.32) | -1.26 |
| Mouse 3                | 4.5 (0.32) | -3.18 | 5.9 (0.15) | -1.72 | 3.1 (0.54) | -2.5 | 7.6 (0.56) | 0 | 6.2 (0.1) | -1.42 |
| Mean (SEM)             | 5.1 (0.35) | -2.8 (0.62) | 6.16 (0.29) | -1.75 (0.21) | 6.2 (0.84) | -1.7 (0.44) | 7.9 (0.49) | 0 | 7 (0.42) | -0.9 (0.44) |
| **Lgr5**               |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 6.7 (0.17) | -1.8 | 7.3 (0.39) | -1.2 | 6.5 (0.4) | -2.02 | 8 (0.23) | -0.54 | 8.5 (0.31) | 0 |
| Mouse 2                | 7.6 (0.05) | -2.2 | 7.3 (0.28) | -2.6 | 7 (0.18) | -2.86 | 9.8 (0.31) | 0 | 9 (0.41) | -0.84 |
| Mouse 3                | 7.4 (0.17) | -2 | 8.6 (0.19) | -0.7 | 6.9 (0.4) | -2.47 | 9.4 (0.64) | 0 | 8.3 (0.23) | -1.04 |
| Mean (SEM)             | 7.23 (0.26) | -2 (0.13) | 7.73 (0.45) | -1.51 (0.55) | 6.79 (0.15) | -2.45 (0.24) | 9.05 (0.56) | -0.18 (0.18) | 8.61 (0.2) | -0.63 (0.32) |
| **Olfn4**              |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | -0.6 (0.1) | -7.39 | -1 (0.25) | -7.8 | -0.6 (0.59) | -7.4 | 6.5 (0.36) | -0.29 | 6.8 (0.38) | 0 |
| Mouse 2                | -0.2 (0.32) | -11.79 | -0.6 (0.08) | -12.15 | 1 (0.27) | -10.6 | 11.6 (0.2) | 0 | 9.3 (0.27) | -2.21 |
| Mouse 3                | -0.3 (0.27) | -9.28 | 0.3 (0.06) | -8.7 | -0.6 (0.45) | -9.5 | 8.95 (1.12) | 0 | 7.5 (1.45) | -1.49 |
| Mean (SEM)             | 0.08 (0.42) | -9.49 (1.27) | -0.44 (0.37) | -9.54 (1.33) | -0.66 (0.58) | -9.15 (0.9) | 11.46 (1.54) | -0.1 (0.1) | 7.87 (0.76) | -1.23 (0.65) |
| **Sox4**               |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 9.1 (0.01) | -2.9 | 10.1 (0.27) | -1.9 | 10 (0.39) | -2 | 11.6 (0.2) | -0.4 | 12 (0.2) | 0 |
| Mouse 2                | 9.9 (0.02) | -2.8 | 10.6 (0.22) | -2.1 | 10.6 (0.21) | -2 | 12.6 (0.4) | 0 | 11.6 (0.3) | -1 |
| Mouse 3                | 9.2 (0.32) | -3.3 | 11 (0.21) | -1.6 | 10.3 (0.28) | -2.2 | 12.5 (0.3) | 0 | 10.7 (0.2) | -1.9 |
| Mean (SEM)             | 9.4 (0.24) | -2.99 (0.18) | 10.55 (0.25) | -1.84 (0.16) | 10.3 (0.17) | -2.09 (0.07) | 12.26 (0.33) | -0.13 (0.13) | 11.43 (0.39) | -0.97 (0.53) |
| **Bmp2**               |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 9.2 (0.32) | 0 | 9.2 (0.09) | -0.1 | 7.3 (0.1) | -1.9 | 7.5 (0.2) | -1.7 | 6.3 (0.5) | -2.9 |
| Mouse 2                | 8.8 (0.11) | 0 | 8.6 (0.22) | -0.3 | 7.2 (0.22) | -1.6 | 8.5 (0.6) | -0.3 | 5.7 (0.2) | -3.1 |
| Mouse 3                | 10.3 (0.27) | 0 | 9.7 (0.41) | -0.6 | 8 (0.62) | -2.2 | 7.2 (0.4) | -3.1 | 5.9 (0.3) | -4.4 |
| Mean (SEM)             | 9.44 (0.43) | 0 | 9.14 (0.32) | -0.3 (0.15) | 9.01 (0.34) | -1.9 (0.17) | 7.71 (0.4) | -1.7 (0.8) | 5.96 (0.16) | 3.48 (0.45) |
| **Axin2**              |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 4.05 (0.04) | -2.4 | 4.03 (0.34) | -2.4 | 4 (0.28) | -2.5 | 6.2 (0.28) | -0.31 | 6.47 (0.1) | 0 |
| Mouse 2                | 4.32 (0.09) | -3.1 | 4.5 (0.24) | -2.9 | 4.3 (0.14) | -3.1 | 7.4 (0.19) | 0 | 5.79 (0.2) | -1.6 |
| Mouse 3                | 3.73 (0.42) | -4.3 | 4 (0.3) | -4 | 4.3 (0.34) | -3.8 | 8.1 (0.1) | 0 | 6.37 (0.55) | -1.7 |
| Mean (SEM)             | 4.03 (0.17) | -3.28 (0.56) | 4.19 (0.15) | -3.13 (0.47) | 4.18 (0.09) | -3.14 (0.37) | 7.21 (0.34) | -0.1 (0.1) | 6.21 (0.21) | -1.1 (0.55) |
| **Ccnd1**              |     |     |     |        |        |     |     |     |        |      |
| Mouse 1                | 4.8 (0.13) | -2.1 | 4.8 (0.25) | -2.1 | 4.2 (0.27) | -2.7 | 6.3 (0.08) | -0.6 | 6.9 (0.22) | 0 |
| Mouse 2                | 5.1 (0.19) | -1.6 | 4.15 (0.19) | -2.5 | 3.7 (0.18) | -3 | 6.7 (0.21) | 0 | 5.7 (0.07) | -1 |
| Mouse 3                | 4.95 (0.33) | -2.4 | 5.8 (0.14) | -1.5 | 3.9 (0.22) | -3.9 | 7.3 (0.44) | 0 | 6.4 (0.19) | -0.9 |
| Mean (SEM)             | 4.96 (0.08) | -2.02 (0.25) | 4.93 (0.48) | -2.05 (0.29) | 3.78 (0.24) | -3.2 (0.37) | 6.78 (0.29) | -0.2 (0.2) | 6.33 (0.37) | -0.65 (0.32) |
|        | EphB2  | Lef1   | EphB3  | Mmp7   | Grem 1 (m) | Grem 2 (m) | Hgf (m) | Sfrp2 (m) |
|--------|--------|--------|--------|--------|-----------|-----------|---------|-----------|
|        | Mouse 1 | Mouse 1 | Mouse 1 | Mouse 1 | Mouse 1   | Mouse 1   | Mouse 1 | Mouse 1   |
|        | 4.8 (0.16) | 11.8 (0.23) | 8.7 (0.17) | 5.6 (0.44) | 4.8       | 7.0       | 8.0       | 13.7      |
|        | Mouse 2 | Mouse 2 | Mouse 2 | Mouse 2 | Mouse 2   | Mouse 2   | Mouse 2 | Mouse 2   |
|        | 2 (0.89) | 14.4 (1.12) | 7.4 (0.13) | 5.3 (0.04) | 0.8       | 11.0      | 7.8       | 15.6      |
|        | Mouse 3 | Mouse 3 | Mouse 3 | Mouse 3 | Mouse 3   | Mouse 3   | Mouse 3 | Mouse 3   |
|        | 4.5 (0.24) | 12.6 (0.07) | 5.7 (0.14) | 6.05 (0.52) | 5.4      | 4.0       | 5.6       | 16.0      |
|        | Mean (SEM) | Mean (SEM) | Mean (SEM) | Mean (SEM) | Mean (SEM) | Mean (SEM) | Mean (SEM) | Mean (SEM) |
|        | 3.75 (0.88) | 12.92 (0.78) | 7.25 (0.88) | 6.25 (0.52) | 5.6      | 2.0       | 2.8       | 3.0       |

**EphB2**
- **Mouse 1**: Mean = 4.8 (0.16), SEM = 0.5
- **Mouse 2**: Mean = 2 (0.89), SEM = 0.8
- **Mouse 3**: Mean = 4.5 (0.24), SEM = 0.8

**Lef1**
- **Mouse 1**: Mean = 11.8 (0.23), SEM = 0.2
- **Mouse 2**: Mean = 14.4 (1.12), SEM = 0.8
- **Mouse 3**: Mean = 12.6 (0.07), SEM = 0.8

**EphB3**
- **Mouse 1**: Mean = 8.7 (0.17), SEM = 0.7
- **Mouse 2**: Mean = 7.4 (0.13), SEM = 0.5
- **Mouse 3**: Mean = 5.7 (0.14), SEM = 0.5

**Mmp7**
- **Mouse 1**: Mean = 5.6 (0.44), SEM = 0.6
- **Mouse 2**: Mean = 5.3 (0.04), SEM = 0.1
- **Mouse 3**: Mean = 6.05 (0.52), SEM = 0.5

**Grem 1 (m)**
- **Mouse 1**: Mean = 4.8, SEM = 0.5
- **Mouse 2**: Mean = 7.3, SEM = 0.8
- **Mouse 3**: Mean = 4.4, SEM = 0.6

**Grem 2 (m)**
- **Mouse 1**: Mean = 7.0, SEM = 0.6
- **Mouse 2**: Mean = 11.0, SEM = 1.0
- **Mouse 3**: Mean = 7.8, SEM = 0.8

**Hgf (m)**
- **Mouse 1**: Mean = 8.0, SEM = 0.6
- **Mouse 2**: Mean = 7.8, SEM = 1.0
- **Mouse 3**: Mean = 8.2, SEM = 0.8

**Sfrp2 (m)**
- **Mouse 1**: Mean = 13.7, SEM = 0.8
- **Mouse 2**: Mean = 15.6, SEM = 0.8
- **Mouse 3**: Mean = 10.8, SEM = 0.8

*Note: The table includes raw data and calculated mean values with standard errors for each parameter measured. The p-values indicate statistical significance of the differences between groups.*
| Epithelial Gene/patient | Duodenum Mean (SEM) ΔCt | ΔΔCt | Ileum Mean (SEM) ΔCt | ΔΔCt | Caecum Mean (SEM) ΔCt | ΔΔCt | Rectum Mean (SEM) ΔCt | ΔΔCt | ANOVA |
|-------------------------|--------------------------|------|----------------------|------|----------------------|------|----------------------|------|-------|
| **LGR5**                |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | 6.7 (0.64)               | -2.4 | 5.5 (0.27)           | -3.6 | 6.2 (0.61)            | -3   | 9.1 (1.1)            | 0    | p<0.001 |
| Patient 2               | 7.5 (0.74)               | -0.8 | 5.3 (0.95)           | -3   | 7.7 (0.46)            | -0.56| 8.3 (0.2)            | 0    |       |
| Patient 3               | 9 (0.55)                 | -1.4 | 5.5 (0.38)           | -3.9 | 9.4 (0.21)            | 0    | 9.4 (0.2)            | 0    |       |
| Patient 4               | 6.6 (0.23)               | -2.3 | 6.2 (0.22)           | -2.7 | 7.8 (0.25)            | -1.1 | 8.9 (0.4)            | 0    |       |
| Mean (SEM)              | 7.2 (0.32)               | -1.74 (0.38) | 5.6 (0.2) | -3.32 (0.29) | 7.8 (0.66) | -1.17 (0.65) | 8.94 (0.24) | 0 |       |
| **OLFM4**               |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | -2 (0.5)                 | -4.5 | -4.1 (0.23)          | -6.6 | 1.6 (0.6)             | -0.9 | 2.5 (1.5)            | 0    | p<0.001 |
| Patient 2               | -2.1 (0.2)               | -3.9 | -2.1 (0.37)          | -3.9 | -1.9 (0.4)            | -3.6 | 1.8 (1.16)           | 0    |       |
| Patient 3               | 0.01 (0.2)               | -4   | -1.8 (0.33)          | -5.8 | -0.6 (0.8)            | -4.6 | 4 (0.3)              | 0    |       |
| Patient 4               | -1 (0.6)                 | -6.6 | -1.9 (0.1)           | -7.5 | -0.6 (0.4)            | -6.2 | 5.5 (0.25)           | 0    |       |
| Mean (SEM)              | -1.29 (0.5)              | -4.8 (0.62) | -2.5 (0.55) | -5.94 (0.77) | -0.37 (0.73) | -3.83 (1.11) | 3.46 (0.84) | 0 |       |
| **BMP2**                |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | 7.8 (0.2)                | 0    | 7.6 (0.2)            | -0.14| 5 (0.6)               | -2.8 | 4.8 (0.1)            | -3   | p<0.001 |
| Patient 2               | 6.5 (0.7)                | -0.9 | 7.3 (0.4)            | 0    | 5.3 (0.3)             | -2   | 4.9 (0.2)            | -2.4 |       |
| Patient 3               | 7.9 (0.5)                | -2.9 | 10.7 (0.7)           | 0    | 6.7 (0.4)             | -4   | 5.1 (0.1)            | -5.6 |       |
| Patient 4               | 8.7 (0.1)                | -0.3 | 9 (0.2)              | 0    | 8.5 (0.3)             | -0.5 | 5.4 (0.5)            | -3.6 |       |
| Mean (SEM)              | 7.7 (0.46)               | -0.99 (0.61) | 8.65 (0.76) | -0.04 (0.04) | 6.38 (0.08) | -2.3 (0.74) | 5.04 (0.13) | -3.65 (0.69) |       |
| **AXIN2**               |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | 5.2 (0.4)                | 0    | 3.8 (0.16)           | -1.4 | 3.9 (0.09)            | -1.3 | 4.2 (0.2)            | -0.9 | p=0.3 |
| Patient 2               | 5.3 (0.6)                | 0    | 4.2 (0.1)            | -1.1 | 4.6 (0.2)             | -0.7 | 3.5 (0.34)           | -1.8 |       |
| Patient 3               | 6.5 (0.1)                | -1.74| 4.5 (0.2)            | -3.8 | 6.3 (0.4)             | -2   | 8.3 (0.2)            | 0    |       |
| Patient 4               | 5.2 (0.2)                | 0    | 4.2 (0.3)            | -1   | 5.2 (0.5)             | -0.1 | 3.8 (0.5)            | -1.4 |       |
| Mean (SEM)              | 5.56 (0.33)              | -0.44 (0.44) | 4.17 (0.14) | -1.8 (0.67) | 4.98 (0.5) | -1.02 (0.42) | 4.95 (1.12) | -1.04 (0.39) |       |
| **CCND1**               |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | 4.6 (0.21)               | -1.2 | 5.8 (0.18)           | 0    | 5.4 (0.18)            | -0.37| 5.6 (0.18)           | -0.2 | p=0.8 |
| Patient 2               | 4.3 (0.19)               | -0.6 | 4.9 (0.39)           | 0    | 4.6 (0.5)             | -0.34| 4.6 (0.36)           | -0.34|       |
| Patient 3               | 5.6 (0.15)               | -0.8 | 6.1 (0.35)           | -0.35| 6.4 (0.1)             | 0    | 6 (0.07)             | -0.45|       |
| Patient 4               | 5.3 (0.17)               | -0.6 | 5.4 (0.19)           | -0.6 | 6 (0.08)              | 0    | 5.9 (0.07)           | -0.01|       |
| Mean (SEM)              | 4.95 (0.3)               | -0.81 (0.13) | 5.52 (0.25) | -0.24 (0.15) | 5.58 (0.39) | 0.18 (0.1) | 5.51 (0.32) | -0.25 (0.09) |       |
| **EPHB2**               |                          |      |                      |      |                      |      |                      |      |       |
| Patient 1               | 1.7 (0.4)                | -1.1 | 1.2 (0.2)            | -1.6 | 2.1 (0.3)             | -0.7 | 2.8 (0.5)            | 0    | p=0.3 |
| Patient 2               | 1.4 (0.3)                | -1.2 | 1.3 (0.01)           | -1.2 | 1.8 (0.2)             | -0.7 | 2.5 (0.2)            | 0    |       |
| Patient 3               | 3.6 (0.2)                | 1    | 2 (0.1)              | -2.5 | 3.5 (0.2)             | -1   | 4.5 (0.04)           | 0    |       |
| Patient 4               | 3.2 (0.44)               | -0.7 | 2.4 (0.1)            | -1.5 | 2.7 (0.3)             | -1.1 | 3.8 (0.2)            | 0    |       |
| Mean (SEM)              | 2.43 (0.52)              | -0.97 (0.11) | 1.74 (0.28) | -1.67 (0.28) | 2.53 (0.36) | -0.88 (0.11) | 3.4 (0.46) | 0 |       |
|        | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Mean (SEM) | p-value |
|--------|-----------|-----------|-----------|-----------|------------|---------|
| **LEF1** | 6.9 (0.42) | 9.2 (0.37) | 8.9 (0.36) | 7.4 (0.76) | 8.1 (0.55) | p<0.01 |
|        | -7.4      | -3        | -3.5      | -3.1      | -4.24 (1.04)|         |
|        | 8.8 (0.4) | 9 (0.6)   | 7.6 (0.3) | 7.5 (0.2) | 8.2 (0.39) |         |
|        | -5.6      | -3.2      | -4.8      | -3        | -4.13 (0.62)|         |
|        | 10.3 (0.5)| 12.2 (0.6)| 11.8 (0.6)| 9.7 (0.4) | 11.01 (0.6)|         |
|        | -4        | 0         | -0.5      | -0.8      | -1.32 (0.92)|         |
|        | 14.3 (1.3)| 12.1 (0.3)| 12.4 (0.3)| 10.5 (0.4)| 12.31 (0.78)|         |
|        | 0         | -0.1      | 0         | 0         | -0.02 (0.02)|         |
| **EPHB3** | 12.9 (0.59) | 14.8 (0.27) | 16 (0.22) | 12.6 (0.55) | 14.05 (0.8) | p=0.05 |
|        | -0.54     | 0         | 0         | -2.22     | -0.69 (0.52)|         |
|        | 11.7 (0.19)| 10 (0.65) | 13.4 (0.55)| 12 (0.74) | 11.78 (0.71)|         |
|        | -1.7      | -4.8      | -2.5      | -2.8      | -2.96 (0.66)|         |
|        | 10 (0.26) | 14.5 (0.62)| 14.8 (0.22)| 14.4 (0.49)| 13.47 (1.13)|         |
|        | -3.3      | -0.3      | -1.1      | -0.4      | -1.27 (0.7)|         |
|        | 13.4 (0.92)| 14 (0.16) | 14.4 (0.15)| 14.8 (0.18)| 14.15 (0.3)|         |
|        | 0         | -0.8      | -1.6      | 0         | -0.59 (0.38)|         |
| **GREM1** | 8         | 7.4       | 8.6       | 8.2       | 8.05 (0.25) | p=0.7 |
|        | -0.3      | -0.3      | -1.3      | -2.2      | -1.03 (0.46)|         |
|        | 7.5       | 7.1       | 8.9       | 8.3       | 7.95 (0.4)|         |
|        | -0.8      | -0.6      | -1        | -2.1      | 1.13 (0.34)|         |
|        | 7.3       | 6.5       | 9.9       | 10.4      | 8.53 (0.96)|         |
|        | -1        | -1.2      | 0         | 0         | -0.55 (0.3)|         |
|        | 8.3       | 7.7       | 9.8       | 9.9       | 8.9 (0.54)|         |
|        | 0         | 0         | -0.1      | -0.5      | -0.15 (0.1)|         |
| **GREM2** | 6.8       | 6.4       | 6         | 8.2       | 6.4 (0.2) | p=0.2 |
|        | -1.1      | -2.2      | -3.1      | fail      | -2.1 (0.5)|         |
|        | 7.9       | 5.3       | 6.8       | fail      | 6.7 (0.65)|         |
|        | 0         | -3.3      | -2.3      | fail      | -1.9 (0.8)|         |
|        | 6         | 7.3       | 7.7       | fail      | 7 (0.4) |         |
|        | -1.9      | -1.3      | -1.4      | fail      | -1.5 (0.16)|         |
|        | 6.9       | 8.6       | 9.1       | fail      | 8.2 (0.6)|         |
|        | -1        | 0         | 0         | fail      | -0.3 (0.3)|         |
| **HGF**  | 5.9       | 6.4       | 5.8       | 6         | 6 (0.16) | p=0.05 |
|        | -4.5      | -2.2      | -3.4      | -2.6      | -3.4 (0.6)|         |
|        | 6.4       | 8.6       | 6         | 5.8       | 7 (0.7) |         |
|        | -4        | 0         | -3.2      | -2.8      | -2.4 (1.06)|         |
|        | 7.1       | 6.2       | 5         | 5.5       | 6.1 (0.5)|         |
|        | -3.3      | -2.4      | -4.2      | -3.1      | -3.3 (0.45)|         |
|        | 10.4      | 8.5       | 9.2       | 8.6       | 9.4 (0.5)|         |
|        | 0         | -0.1      | 0         | 0         | -0.03 (0.03)|         |
| **SFRP2** | 4.8       | 6.8       | 7.6       | 7.8       | 6.4 (0.7) | p=0.25 |
|        | -1.7      | -2.4      | -4.2      | -4.9      | -2.7 (0.6)|         |
|        | 5.85      | 9.6       | 8.4       | 8.7       | 7.95 (0.95)|         |
|        | -0.65     | 0         | -3.4      | -4        | -1.35 (0.9)|         |
|        | 5.4       | 9.4       | 10.6      | 10.6      | 8.5 (1.4)|         |
|        | -1.1      | -0.2      | -1.2      | -2.1      | -0.8 (0.3)|         |
|        | 6.5       | 9.2       | 11.8      | 12.7      | 9.2 (1.3)|         |
|        | 0         | -0.4      | 0         | 0         | 0.13 (0.1)|         |
Supplementary tables 2A and B.

qRT-PCR gene expression data for mouse (supplementary table 2A) and human (supplementary table 2B) whole mount crypts and mesenchymal sections. Each patient or mouse ΔCt value was calculated from the ΔCt values of 4-5 individual crypts or from a single denuded mesenchymal section, for each gene from each region. Mesenchymal genes are indicated by (m). For calculation of ΔΔCt values the region with the lowest gene expression was considered baseline expression for each individual mouse/patient. ΔΔCt values for other regions were calculated against this baseline expression value. The mean (SEM) ΔΔCt (red text) is the average of the individual mouse/patient values and was used to calculate the fold change values plotted in figure 3. ANOVA was used to calculate p values for differences in absolute gene expression between different regions.
## Supplementary table 3

| Patient / Germline mutation | Somatic mutation | Upper GI lesions | Colonic lesions |
|-----------------------------|------------------|------------------|-----------------|
| Patient 1 Deletion ex11-13  | Truncating       | c.4660_61insA p.T1556fs | Rectum Left colon TC 1 TC 2 TC 3 Right AC Caecum |
|                             |                  | c.4393_94del2 p.S1465fs | c.3856G>T p.E1286X c.4265delA p.D1422fs c.4606G>T p.E1536X c.4259delC p.P1420fs c.4483_84insA p.S1495fs c.3871C>T Q1291X c.4742_43del2 p.S1581fs |
|                             | LOH              | No               | Yes             | No   | No  | No   | No   | No   | No   | No   |
|                             | Residual 20AARs  | 3                | 2               | 1,1  | 2   | 2    | 2    | 3    | 1    | 3    |
| Patient 2 c.1660C>T p.R554X, | Truncating       | c.4660_61insA p.T1556fs | Rectum 1 Rectum 2 Rectum 3 DC 1 DC 2 AC 1 AC 2 |
|                             |                  | c.4063_64insT p.S1355fs | p.S1400X c.3942delG p.R1314fs c.4467_71del6 p.L1409fs c.4316delC p.P1439fs c.4464delAT p.L1488fs c.4191del2 p.E1397fs |
|                             | LOH              | No               | No              | Yes  | No  | No   | No   | No   | No   | No   |
|                             | Residual 20AARs  | 3                | 2               | 1,1  | 1   | 2    | 2    | 2    | 2    | 2    |
| Patient 3 c.2055del11 p.W685fs | Truncating      | c.4613insG p.E1538fs | Unspecified colonic location |
|                             |                  | c.4192_93del2 p.S1398fs | c.4308delT p.S1346fs c.4221_22del2 p.S1407fs c.4476delC p.A1492fs c.3883G>T p.E1295X Complex del p.L1423fs |
|                             | LOH              | No               | No              | No   | No  | No   | No   | No   | No   | No   |
|                             | Residual 20AARs  | 3                | 2               | 2    | 2   | 1    | 2    | 1    | 2    |
| Patient 4 c.2387 del2 p.796fs | Truncating      | c.4291delA p.M1431fs | Unspecified colonic location |
|                             |                  | c.4465_66insG p.L1489fs | c.4463delT p.L1488fs |
|                             | LOH              | No               | No              | No   | No  | No   | No   | No   | No   | No   |
|                             | Residual 20AARs  | 2                | 2               | 2    | 2   | 2    | 2    | 2    | 2    |
| Patient 5 c.4387del4 p.K1462fs | Truncating      | c.4012C>T p.Q1338X | Unspecified colonic location |
|                             |                  | c.4348C>T p.R1450X |
|                             | LOH              | NI               | NI              | NI   | NI  | NI   | NI   | NI   | NI   | NI   |
|                             | Residual 20AARs  | 1                | 2               | 2    | 2   | 2    | 2    | 2    | 2    |

**Legend:**
- **LOH:** Loss of Heterozygosity
- **20AARs:** Number of 20 Amino Acid Residues
### Supplementary Table 3. Upper and lower GI polyp mutation profiles in individual FAP patients.

Mutations are classified using standard nomenclature where c stands for complementary DNA sequence followed by the nucleotide number and the nucleotide change and p stands for protein sequence followed by the amino acid code letter change flanking the altered amino acid number. The number of retained 20 amino acid repeats (20AARs) is listed under each mutation. Significantly more 20AARs were retained in upper GI lesions than lower GI polyps (Binomial test, p=0.002) Fs - frame shift; DC - descending colon; TC – transverse colon; AC – ascending colon

| Patient 6 | Truncating | None | Unspecified colonic location |
|-----------|------------|------|-------------------------------|
|           |            | c.2432C>G p.S811X | c.1660C>T p.R554X | c.2432C>G p.S811X | c.694C>T p.R232X | c.994C>T, p.R332X | c.2432C>G p.S811X |
| LOH       | Yes        | No   | No                            | No                  | No                  | No                  | No                  |
| Residual 20AARs | 3         | 0    | 0                             | 0                   | 0                   | 0                   | 0                   |

| Patient 7 c.8136del2 p.2711-12fs | Truncating | c.4660_61insA p.T1556fs | Rectum 1 | Rectum 2 | Rectum 3 | Rectum 4 | Rectum 5 | TC 1 | TC 2 | TC 3 |
|-------------------------------|------------|--------------------------|----------|----------|----------|----------|----------|------|------|------|
| LOH                           | No         | No                       | No       | No       | No       | No       | No       | No   | No   | No   |
| Residual 20AARs               | 3          | 2                        | 3        | 2        | 2        | 2        | 3        | 3    | 2    |      |

| Patient 7 c.8136del2 p.2711-12fs | Truncating | Colonic lesions continued... | UC 4 | UC 5 | AC 1 | AC 2 | AC 3 | AC 4 |
|----------------------------------|------------|-------------------------------|------|------|------|------|------|------|
| LOH                             | No         | Yes                           | No   | No   | No   | No   | Yes   |      |
| Residual 20AARs                 | 2          | 1, 1                          | 2    | 2    | 3    | 1    |       |      |

Unspecified colonic location:
- Colon cancer
- Truncating
- None
- LOH
- Yes
- No
### Supplementary table 4A

| Patient age, gender | Dukes stage | Location | APC mutation 1 | APC mutation 2 | Retained 20AARs |
|---------------------|-------------|----------|----------------|----------------|-----------------|
| 82 F                | NK          | Caecum   | c.3871C>T p.Q1291X | c.645C>T p.R216X | 1, 0            |
| 46 F                | C           | Caecum   | c.3340C>T p.R1114X | c.4343delC p.T1448fs | 0, 2            |
| NK                  | NK          | Caecum   | c.847C>T p.R283X | c.4343delC p.T1448fs | 0, 2            |
| 77 F                | C           | Caecum   | c.4333insAT p.T1445fs | LOH              | 2, 2            |
| 77 M                | NK          | Ascending | c.4348C>T p.R1450X | LOH              | 2, 2            |
| 72 M                | C           | Left     | c.4012C>T p.Q1338X | LOH              | 1, 1            |
| 81 M                | B           | Sigmoid  | c.637C>T p.R213X | c.4231delG p.C1410fs | 0, 2            |
| 71 M                | A           | Sigmoid  | c.3943insA p.R1314fs | c.637C>T p.R213X | 1, 0            |
| 73 M                | B           | Sigmoid  | c.4659del5 p.E1554fs | c.4147insA p.M1383fs | 0, 2            |
| 64 M                | NK          | Sigmoid  | c.4334insCT p.1445fs | LOH              | 2, 2            |
| 86 F                | B           | Sigmoid  | c.847C>T p.R283X | c.3949G>T p.E1317 | 0, 1            |
| 75 M                | B           | Rectum   | c.3927del5 p.E1309fs | LOH              | 1, 1            |
| 65 F                | A           | Rectum   | c.3927del5 p.E1309fs | LOH              | 1, 1            |
| 56 M                | B           | Rectum   | c.3694insC p.1232fs | LOH              | 0, 0            |
| 57 M                | B           | Rectum   | c.4132C>T p.Q1378X | LOH              | 1, 1            |
| 83 F                | C           | Rectum   | c.2460delT p.T820fs | LOH              | 0, 0            |
| 58 M                | B           | Rectum   | c.1860delT p.L620fs | c.4308delT p.S1436fs | 0, 2            |
| 75 M                | NK          | Rectum   | c.3340C>T p.R1114X | LOH              | 0, 0            |
| 64 F                | NK          | Rectum   | c.4263delT p.S1421fs | LOH              | 2, 2            |
### Supplementary table 4B

| COSMIC sample ID | Location | Cumulative total retained 20AAR’s | COSMIC sample ID | Location | Cumulative total retained 20AAR’s |
|------------------|----------|-----------------------------------|------------------|----------|-----------------------------------|
| 736984           | Right    | 5                                 | 1430400          | Left     | 2                                 |
| 874934           | Right    | 2                                 | 736987           | Right    | 4                                 |
| 874961           | Right    | 1                                 | 908482           | Left     | 2                                 |
| 874963           | Right    | 1                                 | 909748           | Left     | 0                                 |
| 874964           | Right    | 1                                 | 990137           | Right    | 4                                 |
| 874965           | Right    | 2                                 | 995381           | Left     | 2                                 |
| 874967           | Right    | 2                                 | 995391           | Right    | 6                                 |
| 874975           | Right    | 1                                 | 995397           | Left     | 4                                 |
| 875010           | Right    | 4                                 | 995400           | Left     | 0                                 |
| 907794           | Right    | 3                                 | 995404           | Left     | 2                                 |
| 908457           | Right    | 2                                 | 995408           | Left     | 4                                 |
| 909755           | Left     | 2                                 | 995409           | Right    | 2                                 |
| 910783           | Left     | 1                                 | 995413           | Left     | 4                                 |
| 995375           | Left     | 2                                 | 1206145          | Left     | 4                                 |
| 995385           | Right    | 5                                 | 1206183          | Left     | 2                                 |
| 995387           | Left     | 2                                 | 1235040          | Right    | 4                                 |
| 995401           | Right    | 3                                 | 1235041          | Right    | 4                                 |
| 995412           | Left     | 3                                 | 1235045          | Right    | 2                                 |
| 995651           | Left     | 3                                 | 1235046          | Left     | 0                                 |
| 1231126          | Left     | 3                                 | 1235051          | Right    | 4                                 |
| 1235039          | Left     | 2                                 | 1235054          | Right    | 4                                 |
| 1235043          | Right    | 2                                 | 1235056          | Right    | 2                                 |
| 1235055          | Left     | 1                                 | 1235058          | Left     | 0                                 |
| 1235057          | Left     | 2                                 | 1235066          | Left     | 2                                 |
| 1235059          | Right    | 2                                 | 1235067          | Left     | 0                                 |
| 1235061          | Right    | 0                                 | 1235068          | Left     | 0                                 |
| 1322285          | Left     | 1                                 | 1235069          | Left     | 2                                 |
| 1322293          | Right    | 3                                 | 1235073          | Right    | 4                                 |
| 1322287          | Right    | 2                                 |                   |          |                                   |

### Supplementary table 4A and B: Sporadic colorectal cancers and cell lines

**Table 4A. Genotyped sporadic colorectal cancers.** 19 sporadic colorectal cancer cases from specified colonic locations were genotyped and two hits at APC were identified. **Table 4B. Publically available data from COSMIC v53.** 57 tumors and cell-lines with positional data and two hits at APC were identified. The number of retained 20 amino acid repeats (20AARs) resultant from the identified mutations is stated. Mutations are classified using standard nomenclature where “c.” stands for cDNA sequence followed by the nucleotide number and the nucleotide change and “p.” stands for protein sequence followed by the amino acid code letter change flanking the altered amino acid number.
Abbreviations M, male; F, female; LOH, loss of heterozygosity (determined by 5q microsatellite analysis); NK, not known.

Supplementary figure legends

Supplementary figure 1
Examples of immunohistochemical staining for cell lineage and apoptosis in wild-type and Ctnnb1\textsuperscript{Δex3} mice.
In wild type mice lysozyme staining for Paneth cells is restricted to cells at the base of crypts. No such positional restriction is seen in the section of a Ctnnb1\textsuperscript{Δex3} mouse where brown stained Paneth cells can be seen the length of the grossly enlarged crypts. Occasional chromogranin A stained cells can be seen in both normal and mutant intestinal crypts but no significant difference in number could be found. Apoptotic cells stained positive for cleaved caspase 3 (black arrows) were uncommon in the normal intestinal crypts but were significantly more prevalent in the dysplastic crypts of Ctnnb1\textsuperscript{Δex3} mice.

Supplementary figure 2
A. Physiological mesenchymal Sfrp2 expression in human and mouse intestinal tracts. Mesenchymal expression of this important Wnt modulator varies considerably along the length of the human and murine intestines, with a reverse gradient seen in the two different species. Mouse colonic mesenchymal SFRP2 expression is greater than 130-fold that seen in the small intestinal mesenchyme.

B. Recombinant Sfrp2 antagonises endogenous Wnt activity in rodent intestinal epithelial cells. Culturing RIE cells with recombinant SFRP2 at physiological (15nM) and supra-physiological (150 and 300nM) concentrations resulted in a dose dependent decrease in Wnt target gene activity as a consequence of endogenous physiological Wnt pathway antagonism.
Supplementary References

1. Poulsom R, Longcroft JM, Jeffery RE et al. A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimens. Eur J Histochem. 1998;**42**(2):121-32.
2. Thirlwell C, Will O, Domingo E et al. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology. 2010 Apr;**138**(4):1441-54, 54.e1-7.
3. Galli LM, Barnes T, Cheng T et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev Dyn. 2006 Mar;**235**(3):681-90.
4. Kress E, Rezza A, Nadjar J et al. The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. J Biol Chem. 2009 Jan 9;**284**(2):1234-41.
5. von Marschall Z, Fisher LW. Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. Biochem Biophys Res Commun. 2010 Sep 24;**400**(3):299-304.